40,705 Shares of Boston Scientific Corporation $BSX Acquired by Van Strum & Towne Inc.

Van Strum & Towne Inc. purchased a new stake in Boston Scientific Corporation (NYSE:BSX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 40,705 shares of the medical equipment provider’s stock, valued at approximately $1,777,000.

Several other large investors have also recently bought and sold shares of BSX. BlackRock Inc. acquired a new position in shares of Boston Scientific in the second quarter valued at approximately $5,534,781,000. Primecap Management Co. CA bought a new position in shares of Boston Scientific during the second quarter worth approximately $2,156,233,000. Jupiter Topco LLC acquired a new stake in Boston Scientific during the 2nd quarter worth approximately $803,357,000. Bank of America Corp DE acquired a new stake in Boston Scientific during the 2nd quarter worth approximately $556,026,000. Finally, Legal & General Group Plc acquired a new stake in Boston Scientific during the 2nd quarter worth approximately $431,890,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Down 2.0%

Shares of BSX stock opened at $44.22 on Friday. The stock has a market cap of $64.10 billion, a P/E ratio of 18.74, a price-to-earnings-growth ratio of 1.34 and a beta of 0.60. Boston Scientific Corporation has a 1 year low of $39.57 and a 1 year high of $105.65. The company has a current ratio of 1.36, a quick ratio of 0.81 and a debt-to-equity ratio of 0.42. The stock has a 50 day simple moving average of $44.05 and a 200 day simple moving average of $54.75.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting analysts’ consensus estimates of $0.73. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The company’s revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the company earned $0.75 EPS. On average, research analysts predict that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

BSX has been the topic of a number of research reports. Wells Fargo & Company decreased their price objective on Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating on the stock in a report on Thursday, October 29th. Needham & Company LLC dropped their target price on Boston Scientific from $57.00 to $48.00 and set a “buy” rating for the company in a report on Wednesday, October 28th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. UBS Group reduced their target price on shares of Boston Scientific from $67.00 to $57.00 and set a “buy” rating for the company in a research report on Thursday, October 29th. Finally, Piper Sandler decreased their price target on shares of Boston Scientific from $65.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $61.43.

Boston Scientific Company Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.